Weihai Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Weihai Chen has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
- Li Zhu
Department of Laboratory Medicine, Suzhou Ninth Hospital Affiliated to Soochow University, Suzhou, Jiangsu, China; Collaborative Innovation Center of Hematology of Jiangsu Province, Soochow University, Suzhou, Jiangsu, China; National Clinical Research &entel for Hematologic Diseases, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
1 shared publication - Xiang-Xiang Li
Department of Clinical Laboratory, Suzhou Ninth Hospital Affiliated to Soochow University, Suzhou, China
1 shared publication
Latest Publications
- Open Access
- 14 April 2026
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 27 (4)
DNA Methylation: A Key Epigenetic Regulator of Cardiovascular Diseases
CVDs arise from the interplay of multiple factors, with genetics and environmental exposures representing key drivers. Accumulating evidence over recent decades has unequivocally established that epigenetic modifications, most prominently DNA methylation, play a pivotal, non-redundant role in the initiation, development, and progression of CVDs. As a critical molecular bridge linking genetic predisposition, environmental insults, and the pathogenesis of CVDs, DNA methylation dynamically mediates crosstalk among these three components, thereby emerging as a core focus for dissecting the underlying pathological mechanisms of CVDs. Thus, this review summarizes the functional roles of DNA methylation in common CVDs, including coronary heart disease (CHD), hypertension, and heart failure (HF). Special emphasis is placed on the regulatory mechanisms of DNA methylation in driving disease pathogenesis, as well as the associated translational potential for preventing CVDs and for clinical management. Moreover, this review delineates the specific pathways through which DNA methylation modulates CVDs onset and progression—providing a novel perspective for in-depth investigation of disease etiologies—and offers a robust theoretical basis for identifying novel therapeutic targets for CVDs. Ultimately, these insights aim to lay a foundation for the optimization and innovation of clinical diagnostic and therapeutic strategies for CVDs.
- 14 April 2026
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 27 (4)
Open AccessDNA Methylation: A Key Epigenetic Regulator of Cardiovascular Diseases
CVDs arise from the interplay of multiple factors, with genetics and environmental exposures representing key drivers. Accumulating evidence over recent decades has unequivocally established that epigenetic modifications, most prominently DNA methylation, play a pivotal, non-redundant role in the initiation, development, and progression of CVDs. As a critical molecular bridge linking genetic predisposition, environmental insults, and the pathogenesis of CVDs, DNA methylation dynamically mediates crosstalk among these three components, thereby emerging as a core focus for dissecting the underlying pathological mechanisms of CVDs. Thus, this review summarizes the functional roles of DNA methylation in common CVDs, including coronary heart disease (CHD), hypertension, and heart failure (HF). Special emphasis is placed on the regulatory mechanisms of DNA methylation in driving disease pathogenesis, as well as the associated translational potential for preventing CVDs and for clinical management. Moreover, this review delineates the specific pathways through which DNA methylation modulates CVDs onset and progression—providing a novel perspective for in-depth investigation of disease etiologies—and offers a robust theoretical basis for identifying novel therapeutic targets for CVDs. Ultimately, these insights aim to lay a foundation for the optimization and innovation of clinical diagnostic and therapeutic strategies for CVDs.